On The Pen™
@ManOnThePen
Followers
3K
Following
881
Media
561
Statuses
2K
Follow for breaking patient centric obesity medicine news from an industry insider.
Joined March 2023
$LLY $NVO $HIMS Effective today, Zepbound price drops via LillyDirect Self-Pay: 2.5mg: $299 (was $349) 5mg: $399 (was $499) 7.5-15mg: $449 (was $499) Without the program? You’re paying $599-$1,049/month for higher doses.
6
3
37
There is a massive and unprecedented story unfolding on TikTok and Reddit. Tens (maybe hundreds) of thousands of people (by my estimate they are mostly younger and of normal BMI), are using the most powerful metabolic modulating drug ever created. #Retatrutide Has there ever
9
2
15
$LLY $NVO $HIMS This 💩 proliferates like wildfire on @tiktok_us yet my extremely respected obesity NEWS account gets banned? This kid is selling retatrutide. Please Retweet and let TikTok know how wildly irresponsible this is.
1
1
7
Reposting to bump
My account was banned at 60k. Goal to get new one to 100k by 2026. Inclined to help? Click the link and comment “followed” below! https://t.co/V3Xycl5ayZ
0
0
2
It really feels like $LLY and Ricks understand that they possess more than a lifetime medicine in Tirzepatide. What they actually possess is the power to transform our entire healthcare system. They’re doing it with D2C and they’re doing it by partnering with Rightway. $CVS
4
0
9
$NVO $HIMS $LLY Medicare negotiated pricing for branded semaglutide is as follows: Ozempic and Rybelsus for Type 2 diabetes, and Wegovy for weight loss: $274 negotiated price, down from around $1,000 list price. Note: Negotiated prices for “higher” doses of Wegovy are $385.
2
0
6
$NVO $LLY $HIMS Novo Nordisk Amycretin Shocker + Semaglutide Flopper
0
0
3
My account was banned at 60k. Goal to get new one to 100k by 2026. Inclined to help? Click the link and comment “followed” below! https://t.co/V3Xycl5ayZ
tiktok.com
@otphq 5047 Followers, 242 Following, 7616 Likes - Watch awesome short videos created by On The Pen Headquarters
4
1
7
$NVO $LLY $VKTX Novo Nordisk just released top line data from the two year evoke and evoke plus trials in early stage Alzheimer’s. Oral semaglutide improved Alzheimer’s related biomarkers but did not slow clinical progression. The extension phase is being discontinued. Full data
3
0
21